Johnson & Johnson Posts Q2 Earnings Beat
Johnson & Johnson reported better-than-expected second-quarter financial results before the markets opened Tuesday.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 259Neos Therapeutics Sets Price for IPO
Neos Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) to price its initial public offering (IPO).
What to Expect From Johnson & Johnson Earnings
Johnson & Johnson is expected to report its second-quarter financial results Tuesday morning before the markets open.
Short Sellers Run for Cover in Big Pharma
The June 30 short interest data have been compared with the previous figures, and across the selected pharmaceutical stocks, short interest decreased.
Short Sellers Back Off Big Biotech
24/7 Wall St. has reviewed the short interest in top biotech companies, without focusing on speculative companies.
Biogen Loses Its Head of Research and Development
Biogen announced on Friday that it is losing its head of research and development at the end of July.
4 Specialty Pharmaceutical Stocks Could Be the Next Takeover Candidates
While there is absolutely no guarantee that any of these companies catch a bid and be bought out, they all have outstanding pipelines and prospects.
Taxing Tobacco to Reduce Smoking
If the World Health Organization (WHO) has its way, increases in national tobacco taxes may curtail tobacco use around the world.
Meet the Next Mega Blockbuster Heart Drug
Novartis is getting ready to steal a lot of hearts with its newest drug. The FDA has approved Entresto tablets for the treatment of heart failure.
3 UBS Must-Own Large-Cap Pharmaceutical Stocks
A new report from UBS highlights three stocks that the firm likes best now. Not only do they all pay a solid dividend and have a good potential for growth, they all could help…
Gensight Biologics Files for Initial Public Offering
Gensight Biologics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
What FDA Breakthrough Therapy Designation Means for Dyax
Dyax announced on Tuesday that the FDA has granted a key breakthrough therapy designation for the investigation of DX-2930 for hereditary angioedema .
Horizon Pharma Makes Hostile Bid to Acquire DepoMed
Horizon Pharma has gone hostile in its attempt to take over DepoMed. These companies have been in talks since March, but an agreement was never reached.
5 Big Upcoming FDA Decisions Expected in July
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of July and added some color.
Big Downside Ahead for Raptor?
ThinkstockRaptor Pharmaceuticals Corp. (NASDAQ: RPTP) was downgraded by Oppenheimer to an Underperform rating from Perform with an $8 price target, implying a downside of about 45% from current prices. Ultimately the brokerage firm recommends…